Senseonics (NYSE:SENS) today announced significant progress with the launch of its Eversense 365 continuous glucose monitor (CGM). In September, the company won FDA clearance for the Eversense 365 one-year implantable CGM. With the clearance, it became the world’s first 365-day CGM system. Senseonics and its global distribution partner, Ascensia Diabetes Care, announced the launch for Eversense 365 […]
NuGen launches needle-free insulin delivery device in Canada
NuGen Medical Devices announced recently that it launched its InsuJet needle-free insulin delivery device in Canada. The company initiated its launch on Nov. 15 — the day after World Diabetes Day. It received an initial order for 2,500, then a second order for 750 units of InsuJet starter kits and consumables. That represents revenue of […]
Cardinal Health recalls certain insulin syringe component packs
The FDA deemed a recall of Cardinal Health (NYSE:CAH) insulin syringe luer lock packs as type I, the most serious kind of recall. This recall relates to the company’s Monoject U-100 mL insulin syringe luer lock with tip cap soft pack (extended conical tip). The device is used to administer insulin under the skin (subcutaneous) or […]
Insulet prevails in IP battle with patch pump maker EOFlow
Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the market-leading Omnipod platform, while Korea-based EOFlow develops the EOPatch — similarly, a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point […]
Embecta to lay off 118 in Massachusetts following patch pump program discontinuation
Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. The state received Embecta’s Worker Adjustment and Retraining Notification (WARN) submission on Nov. 26 — the same day it announced plans to discontinue its insulin patch pump program and restructure. The discontinuation of the patch pump program came not […]
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]
Modular Medical brings in $8.2M
Modular Medical (Nasdaq:MODD) announced recently that it priced an underwritten public offering worth proceeds of around $8.2 million. The San Diego-based insulin pump maker intends to offer more than 5.45 million shares of its common stock at $1.50 per share. It expects proceeds to total $8.2 million before deducting discounts, commissions and estimated offering expenses. The […]
Embecta discontinues insulin patch pump program, plans restructuring
Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after the company announced the discontinuation as part of its fourth-quarter earnings results. The BD Diabetes spinoff won FDA approval for a disposable patch pump system […]
Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both hold FDA approval. The pump administers hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by […]
Medtronic wins FDA nod for new InPen app to support launch with Simplera CGM
Medtronic (NYSE:MDT) announced today that it received FDA clearance for its new InPen insulin delivery system application. The app features missed meal dose detection and paves the way for the launch of the company’s smart multiple daily injection (MDI) system. That system includes the recently FDA-cleared next-generation Simplera continuous glucose monitor (CGM). Medtronic’s smart MDI […]